The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: Implications for clinical management

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Scartozzi, Mario ^a   Faloppi, Luca ^b   Bianconi, Maristella ^b   Giampieri, Riccardo ^a   Maccaroni, Elena ^b   Bittoni, Alessandro ^b   Del Prete, Michela ^b   Loretelli, Cristian ^a   Belvederesi, Laura ^a   Baroni, Gianluca Svegliati ^a   Cascinu, Stefano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED POPPYSEED OIL; LACTATE DEHYDROGENASE; MICROSPHERE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CHEMOEMBOLIZATION; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; BLOOD; DISEASE COURSE; FOLLOW UP; KAPLAN MEIER METHOD; LIVER TUMOR; METHODOLOGY; PROGNOSIS;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84858855476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032653     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. Ca Cancer J Clin 55: 74-108.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, et al. (2002) Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 963: 13-20.
3. Bruix J, Sherman M, (2005) Management of Hepatocellular carcinoma. AASLD Practice Guideline. Hepatology 42: 1208-1236.
4. Okada S, (1998) Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 45 (suppl 3): 1259-1263.
5. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, et al. (2011) Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev May; 37 (3): 169-77 Epub 2010 Aug 25. Review.
6. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
7. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2007) SHARP Investigators. Sorafenib improves survival in advanced Hepatocellular Carcinoma. N Engl J Med Jul 24; 359 (4): 378-90.
8. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. J Nat Cancer Inst 100: 698-711.
9. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-61.
10. Bruix J, Llovet JM, Castells A, Montañá X, Brú C, et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 27: 1578-83.
11. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, et al. (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29: 129-34.
12. Scartozzi M, Svegliati Baroni G, Faloppi L, Di Pietro Paolo M, Pierantoni C, et al. (2010) Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res Dec 15: 29: 164.
13. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-71.
14. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, et al. (2003) Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90: 325-31.
15. Warburg O, (1965) On the origin of cancer cells. Science 123: 309-14.
16. Holbrook JJ, Liljas A, Steindel SJ, (1975) Lactate dehydrogenase. In: Boyer PD, editors. The enzymes, 3rd edition, vol. XI, part A New York Academic Press pp. 191-2.
17. Markert CL, (1963) Lactate dehydrogenase isozymes: dissociation and recombination of subunits. Science 140: 1329-30.
18. Semenza G, (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64: 993-8.
19. Semenza GL, (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-80.
20. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-9.
21. Semenza GL, (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-78.
22. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, et al. (2011) Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clin Cancer Res; Clin Cancer Res Jul 15; 17 (14): 4892-900 Epub 2011 Jun 1.
23. Wu XZ, Ma F, Wang XL, (2010) Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol Aug 28; 16 (32): 4084-8.
24. Kolev Y, Uetake H, Takagi Y, Sugihara K, (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol Aug; 15 (8): 2336-44 Epub 2008 Jun 3.
25. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, et al. (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol May 20; 29 (15): 2004-10 Epub 2011 Apr 4.
26. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, et al. (2011) Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. J Clin Oncol 20 May; 29 (15): 1997-2003 Epub 2011 Apr 4.
27. Chao Y, Li CP, Chau GY, Chen CP, King KL, et al. (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol pp. 55-62.
28. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, et al. (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91: 1354-60.
29. Kohles N, Nagel D, Jungst D, Durner J, Stieber P, et al. (2012) Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing chemoembolization therapy. Tumour Biol Feb; 33 (1): 33-40 Epub 2011 Sep 20.